MPM ASSET MANAGEMENT LLC - Q1 2019 holdings

$243 Million is the total value of MPM ASSET MANAGEMENT LLC's 7 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 50.0% .

 Value Shares↓ Weighting
RYTM  Rhythm Pharmaceuticals, Inc.$84,283,000
+2.0%
3,074,8930.0%34.75%
-50.3%
TCRR NewTCR2 Therapeutics, Inc.$70,607,0004,050,865
+100.0%
29.12%
HARP NewHarpoon Therapeutics, Inc.$42,846,0004,524,425
+100.0%
17.67%
CHMA  Chiasma, Inc.$29,829,000
+67.2%
5,736,2960.0%12.30%
-18.5%
SNDX  Syndax Pharmaceuticals, Inc.$11,386,000
+18.0%
2,168,6910.0%4.70%
-42.5%
CNAT  Conatus Pharmaceuticals, Inc.$2,662,000
-37.6%
2,464,8070.0%1.10%
-69.6%
PETX  Aratana Therapeutics, Inc.$900,000
-41.3%
250,0000.0%0.37%
-71.4%
PRTO ExitProteon Therapeutics, Inc.$0-983,381
-100.0%
-1.89%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2019-05-29
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Chiasma, Inc.24Q2 202119.8%
Aratana Therapeutics, Inc.24Q1 201926.8%
Conatus Pharmaceuticals, Inc.23Q1 20199.7%
Rhythm Pharmaceuticals, Inc.19Q2 202269.9%
Harpoon Therapeutics, Inc.19Q3 202331.9%
Syndax Pharmaceuticals, Inc.19Q3 202014.5%
Radius Health, Inc.17Q2 201876.4%
TCR2 Therapeutics, Inc.17Q1 202329.1%
Proteon Therapeutics, Inc.17Q4 20183.0%
EpiZyme, Inc.15Q4 201635.9%

View MPM ASSET MANAGEMENT LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-14
13F-HR/A2023-09-07
13F-HR2023-08-14
42023-06-05
42023-05-24
13F-HR2023-05-12
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11

View MPM ASSET MANAGEMENT LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (242512000.0 != 242513000.0)
  • The reported has been restated
  • The reported has been amended

Export MPM ASSET MANAGEMENT LLC's holdings